Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACH 000029

Next Previous
Drug Profile

ACH 000029

Alternative Names: ACH-000029

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ache Laboratories
  • Developer Otsuka Pharmaceutical Development & Commercialization
  • Class Anxiolytics; Phenyl ethers; Piperazines; Quinazolines; Quinazolinones; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Alpha 1 adrenergic receptor antagonists; Alpha-1a adrenergic receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin-1D-receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Generalised anxiety disorder; Post-traumatic stress disorders

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Generalised-anxiety-disorder(In volunteers) in Australia (PO, Capsule)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Post-traumatic-stress-disorders(In volunteers) in Australia (PO, Capsule)
  • 02 Nov 2022 Otsuka Pharmaceutical terminates phase I trial in Generalised anxiety disorder (In volunteers) in Australia (PO), due to significant safety issue (SSI) reported(NCT05363839)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top